Drug delivery system comprising an anti-inflammatory agent or a salt thereof for the application to esophageal mucous membranes
AssigneeEsoCap AG
InventorsWerner Weitschies, Christoph Rosenbaum
Life of this patent
Estimating the term…
Abstract
The present invention relates to a drug delivery system for the application to an esophageal mucous membrane, comprising at least one sheet like, in particular film shaped, foil shaped or wafer shaped preparation comprising an anti-inflammatory agent or a salt thereof, a release mechanism, and a trigger mechanism, wherein the trigger mechanism is adapted to trigger, at a predetermined site of action the release of the sheet like preparation by the release mechanism.
Claims20
A drug delivery system for the application to an esophageal mucous membrane, comprising:
- at least one sheet like preparation comprising an active pharmaceutical ingredient;
- a release mechanism;
- and
- a trigger mechanism, wherein
- the trigger mechanism is adapted to trigger, at a predetermined site of action, the release of the preparation by the release mechanism, and wherein the release mechanism is adapted to release said preparation while moving along the esophageal mucous membrane,
- wherein the drug delivery system further comprises a shell, wherein the shell contains the preparation, and wherein the shell comprises an aperture as part of the release mechanism configured to allow said preparation to leave the shell, and wherein the trigger mechanism is a holding device that is a part of or is attached to the preparation, such that the preparation is unrolled or unfolded while the dosage form moves down the esophageal mucous membrane and leaves the shell through the aperture,
- characterized in that the active pharmaceutical ingredient comprises an anti-inflammatory agent or a salt thereof.
The drug delivery system of claim 16, wherein the tyrosine kinase inhibitor is a Janus kinase (JAK) inhibitor selected from the group consisting of upadacitinib (ABT-494), baricitinib, brepocitinib, abrocitinib (PF-04965842), ifidancitinib (ATI-502), tofacitinib, ruxolitinib, delgocitinib (JTE-052), cerdulatinib, gusacitinib (ASN002), and izencitinib (TD-1473).
The drug delivery system of claim 16, wherein the calcineurin inhibitor is selected from the group consisting of sirolimus (rapamycin), tacrolimus (FK-506), pimecrolimus, and cyclosporin A.
The drug delivery system of claim 16, wherein the purine analogue is azathioprine (AZA) or 6-mercaptopurine (6-MP).
Dependencies are inferred from the claim text.